| Rethinking HDL functionality: the emerging roles of sphingosine-1-phosphate and anti-apolipoprotein A1autoantibodies | |  | | 2025 | 8 | 235 |
|
| People living with HIV display increased anti-apolipoprotein A1 auto-antibodies, inflammation, and kynurenine metabolites : a case–control study | Frontiers in cardiovascular medicine |  | | 2024 | 120 | 54 |
|
| Ferritin : a biomarker requiring caution in clinical decision | Diagnostics |  | | 2024 | 103 | 169 |
|
| Associations between high-density lipoprotein particle’s proteome, subfractions and autoantibodies against apolipoprotein A1 in HIV patients | 92nd EAS (European Atherosclerosis Society) Congress | | | 2024 | 12 | 0 |
|
| Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic | Journal of neurology, neurosurgery and psychiatry |  | | 2023 | 274 | 288 |
|
| High antibody titers against apolipoprotein-A1 in NAFLD: a possible link between fatty liver disease and CVD? | 90th European Atherosclerosis Society (EAS) congress | | | 2022 | 165 | 0 |
|
| Sphingosine‐1‐phosphate as a key player of insulin secretion induced by high‐density lipoprotein treatment | Physiological reports |  | | 2021 | 263 | 184 |
|
| Autoantibodies directed against apolipoprotein-A1 as a potential contributor to Non-Alcoholic Fatty Liver Disease | 89th Europen Society of Atherosclerosis (EAS) | | | 2021 | 149 | 0 |
|
| Antibodies against apolipoprotein a-1 as disruptors of cellular cholesterol homeostasis promoting foam cell formation | 88th EAS (European Atherosclerosis Society) Congress | | | 2020 | 75 | 0 |
|
| High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases | Metabolism, clinical and experimental |  | | 2020 | 191 | 0 |
|
| Auto-antibodies against apolipoprotein a-1 block cancer cells proliferation and induce apoptosis | Oncotarget |  | | 2020 | 179 | 140 |
|
| HDL protects against myocardial ischemia reperfusion injury via miR-34b and miR-337 expression which requires STAT3 | PLOS ONE |  | | 2019 | 295 | 223 |
|
| Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation | Journal of clinical medicine |  | | 2019 | 244 | 216 |
|
| P5343 - The presence of anti-apolipoprotein A1 autoantibodies is associated with a pro-atherogenic profile in HIV-infected patients | ESC Congress 2019 together with World Congress of Cardiology | | | 2019 | 124 | 0 |
|
| ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1 | Journal of Immunological Methods |  | | 2019 | 396 | 1 |
|
| Humoral immunity against HDL particle: a new perspective in cardiovascular diseases? | Current Pharmaceutical Design |  | | 2019 | 279 | 0 |
|
| Separation of blood microsamples by exploiting sedimentation at the microscale | Scientific Reports |  | | 2018 | 503 | 258 |
|
| Sphingosine-1-phosphate reduces ischaemia-reperfusion injury by phosphorylating the gap junction protein Connexin43 | Cardiovascular research |  | | 2016 | 703 | 6 |
|
| Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection | Arteriosclerosis, Thrombosis, and Vascular Biology |  | | 2016 | 631 | 1 |
|
| Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury | PloS one |  | | 2015 | 682 | 291 |
|
| CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes | Endocrinology |  | | 2015 | 673 | 1 |
|
| High density lipoproteins and ischemia reperfusion injury: the therapeutic potential of HDL to modulate cell survival pathways | Advances in experimental medicine and biology | | | 2014 | 554 | 0 |
|
| HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity | Atherosclerosis |  | | 2013 | 557 | 0 |
|
| JAK-STAT signaling and myocardial glucose metabolism | JAK-STAT |  | | 2013 | 503 | 1 |
|
| Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/reperfusion injury | Journal of Molecular and Cellular Cardiology |  | | 2013 | 656 | 0 |
|
| HDLs protect pancreatic β-cells against ER stress by restoring protein folding and trafficking | Diabetes |  | | 2012 | 642 | 0 |
|
| The natural cardioprotective particle HDL modulates connexin43 gap junction channels | Cardiovascular research |  | | 2012 | 682 | 4 |
|
| Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins | Current signal transduction therapy | | | 2012 | 576 | 0 |
|
| Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection | Cardiovascular drugs and therapy |  | | 2012 | 640 | 0 |
|
| High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway | JAK-STAT |  | | 2012 | 622 | 384 |
|
| Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis | Cardiovascular research |  | | 2010 | 603 | 0 |
|
| Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate | Cardiovascular research |  | | 2009 | 565 | 0 |
|
| The Prostaglandin E2 – Stat3 connection in hypertrophic and antiapoptotic responses in ventricular cardiomyocytes | |  | | 2008 | 1,030 | 410 |
|
| The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis | Cardiovascular research |  | | 2008 | 655 | 0 |
|